For Immediate Release
Rodolphe Barrangou, PhD, Appointed Editor-in-Chief of The CRISPR Journal
Contact: Kathryn Ryan
914-740-2250
kryan@liebertpub.com
New Rochelle, NY, November 13, 2017—Mary Ann Liebert, Inc., publishers announces the appointment of Rodolphe Barrangou, PhD as Editor-in-Chief of The CRISPR Journal. Launching in early 2018, The CRISPR Journal will be the definitive journal for everything CRISPR and serve as a central forum dedicated to bringing together the globally diverse CRISPR community.
Dr. Barrangou currently serves as the Todd R. Klaenhammer Distinguished Scholar in Probiotics Research and Associate Professor of Food, Bioprocessing and Nutrition Sciences at North Carolina State University (NCSU). Born and educated in Paris, France, Dr. Barrangou moved to the United States for his post-graduate work. He is one of the early pioneers of CRISPR, having made major contributions during his years working at DuPont, prior to joining the NCSU faculty in 2013. Dr. Barrangou has published over 80 CRISPR papers since 2005, including the seminal 2007 study with Philippe Horvath and colleagues which presented the first experimental evidence that the bacterial CRISPR-Cas system provides adaptive immunity against viral infection.
Dr. Barrangou is the author of more than 120 peer-reviewed papers, and an inventor on over 40 issued and pending patents. He is the recipient of numerous prestigious scientific awards, including the 2016 Canada Gairdner International Award, the 2016 Warren Alpert Foundation Prize, and the 2017 National Academy of Sciences (NAS) Award in Molecular Biology. Dr. Barrangou also serves as a scientific advisor to several CRISPR-related biotechnology companies including Caribou Biosciences; he is a co-founder of Intellia Therapeutics and Locus Biosciences.
“We are absolutely thrilled that Rodolphe Barrangou has accepted our invitation to serve as Editor-in-Chief of The CRISPR Journal,” says Kevin Davies, PhD, Executive Editor of The CRISPR Journal and Executive Vice President of Strategic Development at Mary Ann Liebert, Inc., publishers. “Rodolphe needs no introduction to the CRISPR community, having published some of the most critical advances in the field over the past decade that have provided the underpinnings for this exciting new era of gene editing. Far beyond his outstanding scientific reputation and charisma, Rodolphe is bristling with energy and brimming with ideas that will help establish The CRISPR Journal as an essential, impactful journal for the cutting edge of gene editing research and everything CRISPR!”
The CRISPR Journal will be the voice of the global CRISPR community and bring together researchers and practitioners in a wide range of disciplines, including genetics and genomics, cell biology, immunology, infectious diseases, microbiology, molecular biology, neuroscience, plant biology, ethics, and law. In addition to a broad selection of peer-reviewed research, The CRISPR Journal will feature an array of provocative front matter content including editorials, analyses, and commentary.
“This is a very momentous time for the CRISPR field, and The CRISPR Journal provides a voice and unifying common denominator to the various scientific disciplines that constitute the CRISPR community. I am very excited to be part of the Mary Ann Liebert team and have the opportunity to cover all aspects of the CRISPR field,” says Dr. Barrangou.
Dr. Barrangou will guide an established group of luminaries who have thrown their support behind The CRISPR Journal by joining the Editorial Board, including Jennifer Doudna (HHMI/UC Berkeley), Emmanuelle Charpentier (Max Planck Institute, Berlin), George Church (Harvard Medical School), Virginijus Siksnys (Vilnius Institute of Technology), and Eugene Koonin (NCBI).
The CRISPR Journal is actively considering research papers for its inaugural issue, which will be published in early 2018. Potential author inquiries can be sent to editorial@crisprjournal.com. For further information, please visit The CRISPR Journal website.
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Human Gene Therapy, Stem Cells and Development, Cellular Reprogramming, and OMICS: A Journal of Integrative Biology. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s more than 80 journals, books, and trade publications is available on the Mary Ann Liebert, Inc., publishers website.